Voya Investment Management’s Voya MidCap Opportunities Fund underperformed its benchmark in Q4 2025 due to unfavorable stock selection, despite U.S. equity market gains driven by moderating inflation and robust earnings. The fund’s cautious outlook highlights the need for active and flexible positioning to navigate geopolitical risks and policy uncertainty, with a focus on AI-led innovation and sustained corporate capital expenditure.

Vera Therapeutics, Inc. (NASDAQ: VERA) is a clinical-stage biotech company focusing on treatments for kidney diseases, with its lead drug targeting IgA nephropathy. The company was among the top contributors to the fund’s performance in Q4 2025, representing 0.93% of the portfolio investments. Vera Therapeutics, Inc. (NASDAQ: VERA) stock closed at around $45.77 per share on January 22, 2026, with a market capitalization of approximately $3.249 billion.

Vera Therapeutics, Inc. (NASDAQ: VERA) saw positive performance in Q4 2025, driven by favorable phase three clinical trial results for their kidney disease treatment and AI-enabled drug discovery. The company’s success contributed to the fund’s overall performance, along with Comfort Systems USA, Inc., and Dollar Tree, Inc. Vera Therapeutics, Inc. (NASDAQ: VERA) is not among the 30 most popular stocks among hedge funds, but 36 hedge fund portfolios held the stock at the end of the third quarter.

Read more at Yahoo Finance: Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns